As on July 23, 2021, Navidea Biopharmaceuticals Inc. (AMEX: NAVB) started slowly as it slid -4.35% to $1.76. During the day, the stock rose to $1.83 and sunk to $1.74 before settling in for the price of $1.84 at the close. Taking a more long-term approach, NAVB posted a 52-week range of $1.46-$5.02.
It was noted that the giant of the Healthcare sector posted annual sales growth of -41.40% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 33.80%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 37.30%. This publicly-traded company’s shares outstanding now amounts to $28.07 million, simultaneously with a float of $20.70 million. The organization now has a market capitalization sitting at $53.40 million. At the time of writing, stock’s 50-day Moving Average stood at $1.8192, while the 200-day Moving Average is $2.1154.
Navidea Biopharmaceuticals Inc. (NAVB) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Navidea Biopharmaceuticals Inc.’s current insider ownership accounts for 0.40%, in contrast to 6.50% institutional ownership. According to the most recent insider trade that took place on Apr 23, this organization’s Director bought 10,000 shares at the rate of 1.60, making the entire transaction reach 16,000 in total value, affecting insider ownership by 57,000. Preceding that transaction, on Mar 29, Company’s Director bought 21,500 for 2.07, making the whole transaction’s value amount to 44,505. This particular insider is now the holder of 47,000 in total.
Navidea Biopharmaceuticals Inc. (NAVB) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 3/30/2021, the company posted -$0.11 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.08) by -$0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
Navidea Biopharmaceuticals Inc.’s EPS increase for this current 12-month fiscal period is 37.30% and is forecasted to reach -0.40 in the upcoming year.
Navidea Biopharmaceuticals Inc. (AMEX: NAVB) Trading Performance Indicators
Let’s observe the current performance indicators for Navidea Biopharmaceuticals Inc. (NAVB). It’s Quick Ratio in the last reported quarter now stands at 2.10. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 59.33.
In the same vein, NAVB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.45, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be -0.40 at the market close of one year from today.
Technical Analysis of Navidea Biopharmaceuticals Inc. (NAVB)
Through scrutinizing the latest numbers posted by the [Navidea Biopharmaceuticals Inc., NAVB], it can be observed that its last 5-days Average volume of 51540.0 was lower the volume of 0.26 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 38.67% While, its Average True Range was 0.1098.
Raw Stochastic average of Navidea Biopharmaceuticals Inc. (NAVB) in the period of the previous 100 days is set at 28.85%, which indicates a major rise in contrast to 20.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 30.96% that was lower than 56.33% volatility it exhibited in the past 100-days period.